Insulet Corporation ($PODD) Stock Forecast: Down 6.0% Today

What is Insulet Corporation?

A medical device company, Insulet Corporation (PODD), specializes in insulin delivery systems and operates in a highly competitive market where innovation is crucial for improving patient outcomes.

Why is Insulet Corporation going down?

PODD stock is down 6.0% on May 27, 2026 18:41

• Insulet Corporation's stock plummeted to a 52-week low of $143.95, marking a challenging year with a 52.46% decline. The significant drop is linked to a voluntary recall of about 7 million Omnipod insulin pods due to a manufacturing defect. This has raised concerns among investors about product safety and future sales.
• The recall of 7 million patch pumps in the Omnipod product line due to a manufacturing defect leading to insulin leakage and potential medication under-delivery has sparked worries about the company's quality control processes and financial implications, with anticipated costs of up to $50 million this year.
• Despite maintaining a Buy rating, analysts at BTIG have slashed the price target for Insulet Corporation from $260 to $235, indicating revised near-term expectations for the Omnipod product line. This shift has contributed to investor concerns and a reassessment of the company's prospects in the competitive medical device sector.
• The negative outlook for medical device firms is further highlighted by Boston Scientific's stock decline of 6% following a reduction in its full-year guidance. This demonstrates the challenges facing the industry and the broader impact on market performance in the sector.

PODD Price Chart

PODD Technical Analysis

PODD News

Insulet Corporation stock hits 52-week low at $143.95 By Investing.com

Insulet Corporation's stock has dropped to a 52-week low of $143.95, reflecting a challenging year with a 52.46% decline. Despite this, InvestingPro data suggests the stock may be undervalued, and analysts have issued positive ratings. The company recently announced a voluntary recall of approximately 7 million Omnipod insulin pods due to a manufacturing defect.

https://au.investing.com/news/company-news/insulet-corporation-stock-hits-52week-low-at-14395-93CH-4458203

Insulet recalls 7M patch pumps due to leak risk

Insulet has issued a recall for 7 million insulin patch pumps across its Omnipod 5, Omnipod DASH, and Omnipod Insulin Management System devices. This recall is due to a manufacturing defect causing small tears in the tubing, leading to insulin leakage and potential under-delivery of medication, which can result in serious complications like diabetic ketoacidosis. The company has reported 24 serious adverse events, including hospitalizations, but no deaths, and expects to incur up to $50 million in related costs this year.

https://www.medtechdive.com/news/insulet-recalls-7m-patch-pumps-due-to-leak-risk/821232/

Why Insulet Is Dropping 5.7%: BTIG Maintains Buy

Insulet Corporation (PODD) shares dropped 5.7% after BTIG reduced its price target from $260 to $235, while still maintaining a Buy rating. This decrease reflects diminished near-term expectations for the diabetes device maker's Omnipod product line, despite a constructive long-term outlook. The analyst action and resulting sell-off indicate investor repricing of expectations within the competitive medical device sector.

https://news.alphastreet.com/why-insulet-is-dropping-5-7-btig-maintains-buy/amp/

Boston Scientific stock tumbles 6% after guidance cut

Boston Scientific's stock fell over 6% after the company lowered its full-year organic growth guidance to 6.5% to 8%, citing a decline in standalone WATCHMAN growth, reduced Electrophysiology guidance due to competitor launches, and softness in the urology segment. Despite these reductions, management expects to achieve margin improvement and double-digit EPS growth. The company plans to provide an update on its long-range plan, including 2027 and 2028 projections, after the third-quarter earnings call.

https://www.investing.com/news/stock-market-news/boston-scientific-stock-tumbles-6-after-guidance-cut-4712376

Phillips 66 To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Wednesday

This article compiles

https://www.benzinga.com/news/26/05/52802370/phillips-66-to-rally-around-22-here-are-10-top-analyst-forecasts-for-wednesday

Trending Today

Binance Coin ($BNB) Crypto Forecast: Up 5.2% Today

Prime Medicine ($PRME) Stock Forecast: Up 6.5% Today

Hewlett Packard Enterprise Company ($HPE) Stock Forecast: Up 13.1% Today

Ford Motor Company ($F) Stock Forecast: Up 5.3% Today

Broadcom Inc. ($AVGO) Stock Forecast: Up 5.0% Today

Microsoft Corporation ($MSFT) Stock Forecast: Up 5.3% Today

Kimberly-Clark Corporation ($KMB) Stock Forecast: Down 2.8% Today

Palo Alto Networks Inc. ($PANW) Stock Forecast: Up 9.4% Today

Clorox Company (The) ($CLX) Stock Forecast: Down 5.6% Today

Crowdstrike Holdings Inc. ($CRWD) Stock Forecast: Up 8.5% Today

Insulet Corporation Price History

27.04.2026 - PODD Stock was down 6.0%

• The recall of approximately 7 million Omnipod insulin pods due to a manufacturing defect causing insulin leakage has led to a loss of investor confidence in Insulet Corporation.
• The voluntary medical device correction announcement, along with the expected costs of up to $50 million in 2026, has raised concerns about the company's financial performance and operational efficiency.
• The identified cause of the manufacturing issue, the implementation of corrective actions, and the provision of free replacements show Insulet's commitment to product quality and customer safety, but the market reaction remains negative due to the potential impact on sales and reputation.

27.04.2026 - PODD Stock was down 6.0%

• Insulet Corporation's stock plummeted to a 52-week low of $143.95, marking a challenging year with a 52.46% decline. The significant drop is linked to a voluntary recall of about 7 million Omnipod insulin pods due to a manufacturing defect. This has raised concerns among investors about product safety and future sales.
• The recall of 7 million patch pumps in the Omnipod product line due to a manufacturing defect leading to insulin leakage and potential medication under-delivery has sparked worries about the company's quality control processes and financial implications, with anticipated costs of up to $50 million this year.
• Despite maintaining a Buy rating, analysts at BTIG have slashed the price target for Insulet Corporation from $260 to $235, indicating revised near-term expectations for the Omnipod product line. This shift has contributed to investor concerns and a reassessment of the company's prospects in the competitive medical device sector.
• The negative outlook for medical device firms is further highlighted by Boston Scientific's stock decline of 6% following a reduction in its full-year guidance. This demonstrates the challenges facing the industry and the broader impact on market performance in the sector.

27.04.2026 - PODD Stock was down 7.4%

• The downturn in Insulet Corporation's stock (PODD) is linked to a recall of around 7 million Omnipod insulin pods due to a manufacturing flaw causing insulin leakage, raising concerns about product quality and impact on sales and revenue.
• Boston Scientific’s stock decline by over 6% post a reduction in full-year organic growth guidance potentially influenced negative investor sentiment in the healthcare sector, triggering a wider sell-off affecting companies like Insulet Corporation.
• Despite Insulet Corporation's efforts in rectifying the manufacturing issue through a voluntary correction, the projected costs of up to $50 million in 2026 and the subsequent impact on adjusted results likely pressured the stock price further.
• Ongoing industry uncertainties, exemplified by challenges faced by Boston Scientific and Insulet Corporation, are contributing factors to the bearish trend observed in Insulet Corporation's stock (PODD) today.

06.04.2026 - PODD Stock was down 7.3%

• Despite Insulet Corporation (PODD) posting strong Q1 2026 results that exceeded revenue and EPS projections, the stock faced a bearish trend.
• Concerns arose among investors due to the seasonal decrease in new customer starts in Q1, possibly impacting expectations for future growth.
• The stock's bearish movement could be influenced by Q2 revenue guidance slightly falling below analyst forecasts, hinting at potential obstacles ahead.
• Investors may have responded to the stock's immediate surge post-earnings announcement by capitalizing on profits, contributing to today's observed bearish movement.

06.04.2026 - PODD Stock was down 10.9%

• Insulet Corporation posted robust financial results for the first quarter of 2026, surpassing revenue expectations. However, the stock (PODD) witnessed a downward trend in trading.
• The market response may be attributed to the company's slightly lower Q2 CY2026 revenue guidance compared to analyst projections, despite the positive Q1 performance.
• Investor apprehension could be linked to the recent recall of Insulet's Omnipod 5 devices, leading to $12 million in expenses, although this did not impact new customer acquisitions.
• A temporary slowdown in new customer acquisitions during Q1 might also be influencing the bearish movement, as investors keep a close watch on Insulet's growth trends amidst market uncertainties.

30.03.2026 - PODD Stock was up 5.4%

• The bullish movement in Insulet's stock today could be attributed to a disclosure of a significant stake by Vanguard, indicating confidence from a major investment firm.
• Additionally, the anticipation surrounding Insulet's first-quarter earnings release might have fueled investor optimism, especially considering the company's focus on diabetes technology aligning with the current healthcare trends.
• Despite the positive factors, it's essential to note that the stock experienced a significant drop recently, possibly due to concerns raised by the clarification regarding Serious Adverse Events versus FDA device reports, which could have initially impacted investor sentiment negatively.
• Overall, the combination of positive investment news, upcoming earnings release, and recent market fluctuations likely contributed to the bullish movement in Insulet's stock today.

30.03.2026 - PODD Stock was down 7.3%

• Insulet Corporation's stock (PODD) dropped by over 11%, marking its largest decline since May 2020, reflecting strong bearish sentiment.
• The market's negative response may stem from Insulet's clarification on Serious Adverse Events, differing from the FDA's reports, causing investor concerns.
• Sector-wide selling in the medical devices industry affected companies like GE HealthCare Technologies and DexCom, contributing to the downturn in Insulet's stock.
• Despite Mizuho's reduced price target for GE HealthCare shares due to macro concerns, steady demand for imaging equipment and GE HealthCare's pursuit of tariff reimbursement might have diverted investors' focus from Insulet, leading to PODD stock's bearish movement.

01.04.2026 - PODD Stock was up 5.0%

• Concerns about decreasing product moats and distribution led to a downgrade of Insulet Corporation (PODD) by Rothschild & Co Redburn, resulting in a reduction in price target. However, despite this, Truist reiterated a Buy rating, predicting positive Q1 performances.
• The stock experienced a day low under price pressure, reflecting a year-to-date decrease and profitability difficulties, despite consistent long-term net sales growth.
• Questions were raised about Insulet's risk strategy following a voluntary medical device correction, yet this also highlighted the company's commitment to product quality and innovation, resulting in notable growth and increased free cash flow.
• Insulet Corp's stock has outperformed some competitors, surging by 7.6% with GF Value™ indicating an undervaluation of 55.6%. This suggests strong growth and profitability potential. Additionally, insider purchases demonstrate confidence in the company's future prospects.

13.04.2026 - PODD Stock was down 5.1%

• The stock of Insulet rose by 3.4% after the initiation of coverage by Benchmark, demonstrating a positive outlook despite its significant yearly decrease.
• The stock's upward movement was also fueled by the announcement of its strategic expansion into the Middle East and North Africa through a new regional headquarters.
• The ongoing investor interest in Insulet’s user-friendly diabetes management solutions is evident from the positive market response, despite the stock's overall downtrend this year.
• Insulet's consistent gains while major indices were experiencing mixed trading showcase the company's resilience and potential for growth compared to the broader market.

07.04.2026 - PODD Stock was up 5.4%

• Insulet Corporation (PODD) witnessed a strong bullish movement attributed to its impressive Q1 2026 earnings, surpassing expectations with a notable EPS of $1.42 and achieving 30% revenue growth.
• The company's heightened full-year revenue guidance of 21-23% underscores its robust performance and growth potential, fostering increased investor confidence.
• Despite a few analysts revising down price targets, the general market sentiment remains optimistic, focusing on Insulet's excellent financial standing and continuous advancements in the medical device industry.
• A dip in gross margin stemming from a recent correction in medical devices did not sway investors, with the company upholding solid operating and free cash flow, indicating resilience and strategic capital returns.

07.04.2026 - PODD Stock was up 6.8%

• Insulet (PODD) stock saw a 6.3% surge after surpassing expectations in their Q1 results and raising their full-year revenue outlook. This growth was primarily fueled by strong international Omnipod sales and improved profitability.
• Despite concerns over second-quarter guidance and anticipated revenue growth slowdown, Truist Securities reduced Insulet's price target to $250 from $315 but still maintains a Buy rating, anticipating positive results in the future.
• Insulet posted impressive Q1 2026 earnings, beating expectations with an EPS of $1.42, achieving a 30% revenue growth, and expanding their operating margin. Their optimistic full-year revenue guidance and focus on innovation and global expansion contributed to the positive stock movement.
• Analysts are adjusting price targets based on a balance of strong financial performance and valuation worries, with RBC Capital remaining optimistic about Insulet's exceptional financial standing while adjusting the price target to $280.

14.04.2026 - PODD Stock was down 5.5%

• Insulet Corporation's stock hit a 52-week low and dropped 6.7% due to nine analyst downgrades and price target cuts, reflecting a fundamental reassessment of the company's near-term prospects.
• Despite strong Q1 financial results, concerns about guidance and valuation led to a significant decline in the stock price.
• The coordinated action of analyst firms, including Barclays maintaining an Underweight rating, suggests potential uncertainties regarding Insulet's competitive dynamics or guidance revisions.
• Benchmark initiating coverage and a 3.4% rise in shares amid a challenging year-to-date performance indicate ongoing interest in Insulet's user-friendly solutions for diabetes management, despite today's bearish market movement.